Classifications

• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
  • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
  • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
  • G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
  • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10S436/00—Chemistry: analytical and immunological testing
  • Y10S436/80—Fluorescent dyes, e.g. rhodamine
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
  • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10S436/00—Chemistry: analytical and immunological testing
  • Y10S436/805—Optical property
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
  • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10S436/00—Chemistry: analytical and immunological testing
  • Y10S436/807—Apparatus included in process claim, e.g. physical support structures
  • Y10S436/808—Automated or kit
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
  • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10S436/00—Chemistry: analytical and immunological testing
  • Y10S436/823—Immunogenic carrier or carrier per se
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
  • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
  • Y10T428/00—Stock material or miscellaneous articles
  • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
  • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
  • Y10T428/2991—Coated

Definitions

• the method according to the present invention differs from the previous methods essentially by the fact that as a marker to detect or determine the complex formed between a specific binding protein and the corresponding bindable substances there are used latex particles which can be detected visually due to their capability to absorb light in the visual spectrum, or to emit light after irradiation.
• the former detection is based on colour, the latter on fluorescence.
• the present invention is concerned with a method of qualitatively or quantitatively determining a component of a complex formed between at least one specific binding agent, which preferably is a specific binding protein, and its corresponding bindable substance.
• Said method comprises labelling at least one component of said complex with a marker which is easier to determine than the complex itself, whereby the marker used consists of latex particles which can be detected visually due to their capability to absorb light in the visual spectrum, or to emit light after irradiation, the former detection being based on colour, the latter on fluorescence.
• the marker consists of coloured or colourable latex particles and the determination is based on the colour characteristics of the latex particles as such or, in the instance that colourable latex particles are used, on the colour characteristics of the coloured particles derived therefrom.
• the colour, respectively fluorescence signal is, if necessary after development, easily detected and optionally quantified.
• the method is essentially based on the fact that the specific binding agents or any agents bindable thereby, when brought into contact with the latex particles under appropriate conditions, do strongly adsorb thereon without loosing their affinity for their binding or bindable counterpart and that the signal density of the particles is sufficient to allow the detection and/or quantification of small concentrations and amounts.
• the thus labelled specific binding agents or bindable agents when allowed to interact with their counterparts will attach their label to the complex formed during the interaction and consequently the detection thereof can be easily performed making use of the optical properties of the latex particles, especially of their fluorescence and colour characteristics.
• the latex particles for use in the method according to the invention are meant to include any aqueous dispersion of synthetic homopolymers or copolymers containing moieties which can, if necessary after development, absorb light in the visual spectrum or emit light after irradiation.
• the said moieties can either be covalently bound to the polymers, e.g. the polymers comprise recurring units carrying such a moiety, or can be incorporated in the latex particles, e.g. when a molecule containing such a moiety is solvatated in the latex particle.
• the latex particles for use in the method according to the present invention are detectable on basis of their colour.
• Particularly preferred latex particles are those wherein the colour is due to recurring units carrying a light absorbing moiety or which can be chemically converted into such moiety, e.g. by the oxidative coupling of the latter with an aromatic primary amino compound to form a dye.
• coloured and colourable latexes are well-known in the art and comprise, for example, homo- or copolymers of metacrylamide units wherein the amide nitrogen atom is chemically bound to a coloured or colourable residue.
• metacrylamide monomers carrying a coloured residue and their preparation will be found e.g. in Shih, Yen Jer, "COLORED LATEXES: PREPARATION, CHARACTERIZATION AND APPLICATION", Lehigh University (l98l).
• a typical preparation comprises an emulsion polymerization of styrene monomer, seeded polymerization with reactive halogenated monomer, amination with N -methylaniline and a coupling reaction with a diazonium salt, e.g. a benzenesulfonate diazonium salt.
• a diazonium salt e.g. a benzenesulfonate diazonium salt.
• the coloured latexes may contain different chromophores, such as, for example, anthraquinone residues.
• Colourable latexes which can be used in accordance with the present invention include, e.g., the various types of colour complex latexes used in photographic colour film.
• homo- or co-polymers comprising recurring units carrying a moiety capable of oxidatively coupling with an aromatic primary amino compound to form a dye.
• Examples of monomeric colour couplers used according to the present invention can be found e.g. in the Belgian Patent Specifications 584,494, 602,5l6 and 669,97l, in the United Kingdom Patent Specifications 967,503, l,l30,58l; l,247,688; l,269,355; and in the United States Patent Specification 3,356,686.
• monomeric colour couplers are: 2-methylsulfonylamino-5-methacrylaminophenol; 2-methylsulfonylamino-4-chloro-5-methacrylaminophenol; 2-phenylsulfonylamino-5-methacrylaminophenol; 2-(4-chlorophenyl)sulfonylamino-5-methacrylaminophenol; 2-(4-sec.butylphenyl)sulfonylamino-5-methacrylaminophenol; 2-ethoxycarbonylamino-5-methacrylaminophenol; 2-n.butylureido-5-methacrylaminophenol; 2-benzoylamino-5-methacrylaminophenol; 2- o -methylbenzoylamino-5-methacrylaminophenol; 2-acetylamino-5-methacrylaminophenol; 2- p -methoxybenzoylamino-5-methacrylamino
• polymeric compounds e.g. polymeric couplers for use according to the present invention
• equivalent molecular weight is understood the number of grams of polymer containing l mole of polymerized monomeric compound with the chemically reactive moiety, e.g. monomeric coupler. It can be compared with the molecular weight of the non-polymeric classical non-migratory chemically reactive compound, e.g. coupler.
• the equivalent molecular weight of polymeric latex compounds according to the invention can vary within very wide limits, preferable from 200 to 2000.
• the latexes used in the present invention can be prepared by emulsion polymerization using a polymerization initiator as described e.g. in the United States Patent Specification 3,926,436 and United Kingdom Patent Specification No. l,l30,58l.
• polymerization initiators suitable for use in the emulsion polymerization process are e.g. persulfates such as ammonium and potassium persulfate, azonitrile compounds such as 4,4′-azo-bis(4-cyanovaleric acid) and likewise peroxide compounds e.g. benzoylperoxide.
• persulfates such as ammonium and potassium persulfate
• azonitrile compounds such as 4,4′-azo-bis(4-cyanovaleric acid)
• peroxide compounds e.g. benzoylperoxide.
• the aqueous dispersion of the present polymer particles i.e. the latex for use in the method according to the present invention may contain conventional emulsifiers.
• Emulsion polymerization methods of a solid water-insoluble monomer coupler in water are described in U.S.Pat. No. 4,080,2ll and Belgian Pat. No. 669,97l.
• a first polymerization method comprises dissolving a solid water-insoluble monomer coupler in an ethylenically unsaturated copolymerizable monomer and an organic solvent which may be completely water-miscible or poorly water-miscible, then adding the resulting solution to an aqueous reaction medium containing an emulsifier and initiating polymerization.
• the organic solvent suited for use in this method must satisfy the following requirements : (l) it is substantially inert to the solid water-insoluble monomer coupler, (2) it does not interrupt the normal action of the free-radical addition polymerization, and (3) it has a low boiling point which makes it possible to easily remove it from the aqueous reaction medium by distillation during and/or after the polymerization.
• the poorly water-miscible solvent has preferably a boiling point of at most l30°C and a sufficiently high vapour pressure so that it can still be removed readily from the aqueous dispersion by applying a vacuum of 665 to l5 mbar at a temperature of 25° to 80°C.
• suitable solvents are methylene chloride, ethyl formate, n-butyl formate, ethyl acetate, n-propyl acetate, isopropyl acetate, butyl acetate, methyl propionate, ethyl propionate, diethyl carbonate, carbon tetrachloride, sym.
• a second polymerization method comprises dissolving a solid water-insoluble monomer coupler in an ethylenically unsaturated copolymerizable monomer, then adding the resulting solution to an aqueous reaction medium containing an emulsifier and a substance initiating polymerization.
• a third polymerization method comprises dispersing a solid water-insoluble monomer coupler and an ethylenically unsaturated copolymerizable monomer or a solid water-insoluble monomer coupler, an ethylenically unsaturated copolymerizable monomer and an organic solvent in an aqueous reaction medium containing an emulsifier and a substance initiating polymerization.
• the hydrophobic monomer is dispersed in the absence of an organic solvent so that no such solvent has to be removed from the eventually obtained latex. It may be advantageous, however, particularly when the dispersion proceeds with difficulty, to dissolve the monomer first in said already mentioned poorly water-miscible organic solvent(s) and to remove the solvent(s) later on.
• the latex polymer of the present invention comprises still other repeating units that are colourless.
• These repeating units are derived e.g. from a monomer or mixture of monomers providing particular physical characteristics to the latex e.g. improved thermal stability, and improved compatibility with hydrophylic binders e.g. gelatin.
• Colourless ethylenically unsaturated monomers that are chemically inert in the sense as defined and that are copolymerisable with the monomers according to general formula (I) are e.g.
• the stability of the latexes used according to the invention may be improved by structural units of an ionogenic comonomer containing at least one long hydrophobic group, e.g. containing at least 8 carbon atoms, and of a strong hydrophilic group, e.g. sulfonic acid, sulfuric acid or phosphonic acid group or salt thereof.
• an ionogenic comonomer containing at least one long hydrophobic group, e.g. containing at least 8 carbon atoms
• a strong hydrophilic group e.g. sulfonic acid, sulfuric acid or phosphonic acid group or salt thereof.
• the particle size of the latexes prepared with the monomers is generally smaller than l00 nm, in most cases smaller than 70 nm.
• the preferred colourable latex particles to be used according to the method of the present invention comprise a polymer selected from the group consisting of a polymer of formula wherein k is from 30 to 60 and y is from 40 to 70 w/w; a polymer of the formula wherein n is from 20 to 70, m is from 30 to 60, and p is from 0 to 40; a polymer of the formula wherein k is from 30 to 60, y is from 20 to 70, and z is from 0 to 40; a polymer of the formula wherein n is from 20 to 70, m is from 0 to 40, and p is from 30 to 60, and a polymer of the formula wherein n is form 40 to 70 and m is from 30 to 60.
• the numbers represented by the symbols k, y, n, m, p and z are precentages by weight.
• Surface-active agents e.g. anionic, cationic and non-ionic surface active agents, which are useful in the dispersing of non-self-dispersing monomers may be used too in the dispersing of the hydrophobic substance to be incorporated and/or adsorbed to the latex particles.
• Such substances are described e.g. in U.S. Patent No. 3,9l2,5l7.
• the labelling of the specific binding agents or preferably of the specific binding proteins with the coloured or colourable latex particles is easily carried out following the methodologies used for the coating of plastics with proteins, including antibodies.
• the coating is easily effected by contacting the particles in an aqueous medium of appropriate pH wherein the desired proteins are dissolved. After a suitable period of time, the excess of protein is removed by repeated centrifugation and washing of the sediment with fresh buffer. After completion of the washing procedure, the latex particles are re-suspended in an aqueous medium which preferably contains an inert protein, e.g. bovine serum albumin, in order to protect the particles from non-selective interactions with non-specific proteins of the test samples.
• an inert protein e.g. bovine serum albumin
• the proteins can also be bound covalently to the latex particles following the procedure described in U.S. Pat. No. 3,857,93l using a water soluble carbodiimide coupling agent.
• the determinations to be made according to the method of this invention may be performed homogeneously or heterogeneously. Homogeneous determinations are particularly simple to perform but require a measurable change of the perceived signal arising from either those latex particles present in the labelled reagent or in the labelled complex formed between the labelled reagent and the particles to be determined. In those instances where no such distinction is possible, heterogeneous determinations will have to be performed.
• Homogeneous determinations are advantageous due to the fact that it is not necessary to physically separate the bound and unbound labelled species, thus reducing the number of steps necessary to perform an assay.
• the reaction between the labelled component and the corresponding binding counterpart causes the measurable change in the label's participation in or modulation of the signal generating moiety necessary to perform a homogeneous determination.
• the distribution of the latex particles between the bound and unbound species may be differentiated by the inability or altered ability of the said latex particles to affect the signal arising therefrom when present in the bound species.
• a homogenous determination may conveniently be performed according to art-known procedures such as, for example, the competitive binding technique.
• the sample containing the analyte is combined with a binding counterpart of the analyte, a labelled reagent comprising a latex particle coupled to the analyte or a specific binding analogue thereof, and if necessary, the other components necessary to convert the precursor of the signal generating moieties in the latex particle to the signal generating moiety itself.
• a sequential determination may be performed whereby the sample and the analyte binding counterpart are first combined and thereafter the detectant reagent added.
• the determination of antibiotics or other binding proteins, receptors, antibodies having specificity for a particular antigen or hapten or binding materials in general can also be performed following a direct technique.
• the liquid medium containing the component to be detected is combined with a labelled reagent comprising a latex particle coupled to a binding counterpart of the analyte and, if necessary, the other components to convert the precursor of the signal generating moieties in the latex particle to the signal generating moieties themselves, whereafter the signal arising from the latex particles which is altered due to the binding, is measured.
• a heterogeneous determination system comprises three basic constituents which are combined simultaneously or subsequently, i.e. the analyte to be detected, a binding counterpart of the analyte and the labelled reagent, where necessary along with other components necessary to convert the precursor of the signal generating moiety in the label to the signal generating moiety itself. If necessary after an appropriate incubation period or periods the labelled reagent becomes bound to the particles to be detected whereby the ratio of the bound species to the unbound species is a function of the amount of analyte being present. The bound and unbound species are physically separated and the amount of label being present in one thereof is determined.
• the said separation may involve conventional techniques such as, for example, by employing a solid-phase antibody or antigen, a second antibody, or a solid-phase second antibody; or by the use of immuno complex precipitation agents, adsorbents, etc.
• the said binding reactions may for example include the so-called competitive binding technique, the sequential saturation technique, the "sandwich technique", etc.
• the preferred determinations to be made according to the method of this invention are heterogeneous determinations which are generally based on the principle that the labelled complex formed between the specific binding protein and the bindable substances is at some time immobilized in such manner that any un-reacted particles can be washed off, whereupon the immobilized particles are detected in situ or, if desired, after disengagement in any other phase derived therefrom.
• the bindable substance to be detected which may be contained in a crude test specimen or in a purified or partly purified fraction derived therefrom, is immobilized on an appropriate immobilizing support prior to its complexing with the labelled binding protein, specific to said bindable substance.
• the immobilization of the bindable substance may be carried out following the usual techniques, e.g. by spotting an aliquot of the test specimen on the immobilizing support or by immersing the latter in the test sample and subsequently drying and optionally washing off non-immobilized material. This is the so-called direct technique.
• immobilizing supports for this technique use can be made of various materials, in general polymeric materials like, nitrocellulose, diazobenzyloxymethyl (DBH)- and diazophenylthioether (DPT) modified cellulose paper, paper, paper or cellulose acetate activated with cyanogen bromide, agarose, nylon, plastics, etc. which may take any form which is convenient for the determination process, e.g. sheets, beats, welled plates, dip-sticks, etc.
• DDH diazobenzyloxymethyl
• DPT diazophenylthioether
• the support is then brought into contact with a suspension of the coloured or colourable latex particles coated with the specific binding protein under conditions which allow complex formation between the binding protein and the corresponding bindable substances.
• a surface active agent like, for example, a polyoxyethylene fatty acid ester (e.g. Tween®). Consequently, at the sites where the bindable substance is immobilized, coated latex particles will be immobilized in turn in amounts proportional to the concentration of the immobilized bindable substance.
• the immobilized bindable substance is first allowed to react with a first binding protein which is specific therefor and subsequently the thus immobilized fase is brought into contact with the coloured or colourable particles coated with a second binding protein which is specific for said first binding protein.
• the direct method is usually employed with relatively pure or purified test samples or fractions.
• the direct method will often be less suitable, as the non-specific immobilization of a large excess of non-desired material will interfere with the sensitivity and specificity of the determination.
• sandwich technique In order to avoid this problem, which is particularly important with regard to routine analyses, use is very often made of an indirect or so-called sandwich technique.
• a purified or enriched primary specific binding protein is immobilized on a solid support.
• the latter is contacted with the test sample under conditions which allow the complexing of the corresponding bindable substances, which consequently become immobilized themselves.
• the latter After removal of the test sample and washing of the support, the latter is contacted with a suspension of coloured or colourable latex particles coated with secondary specific binding proteins which are able to bind to uncomplexed sites of the immobilized bindable substance.
• the detection of the coloured or colourable latex particles is both convenient and simple. When the particles are already coloured their presence can be observed visually, optionally using a microscope or optionally using a colorimeter or spectrophotometer. Colorimetric or spectrophotometric determinations will be preferred when quantitative determinations are desired.
• the coloured signal can be observed at the binding side itself or, after disengagement, in the resulting suspension or any fraction or phase derived therefrom.
• colourable particles When colourable particles are used instead, it will be necessary to convert them prior to the evaluation into the corresponding coloured particles by allowing them to react with the particular reagents known to be effective for effecting such conversion.
• colour couplers of the type described hereinabove it will be appropriate to contact the particles first with a strong oxidant, such as a peroxide, perborate, peroxoic acid or preferably persulfate and thereafter with a photographic developer, e.g. a phenylene diamine.
• the specific binding proteins which can be employed in the method according to the invention can be of various natures but will in many instances be antibodies to specified antigens or haptens.
• specific binding substances other than antibodies there can be mentioned lectins, which specifically bind glycoproteins and Staphylococcus protein A which specifically binds immunoglobulins of various animal species.
• Antibodies may be polyclonal or monoclonal, the latter having the advantage of being more specific.
• the binding reaction will in almost all cases be allowed to proceed under mild conditions.
• the reaction mixture will in general be an aqueous medium with any desirable organic cosolvents being present in minor amounts.
• the temperature of the reaction will be maintained at a constant level in normal circumstances throughout the incubation period and the enzyme measurement step. Temperatures will generally be between 5 and 50°C, more usually between 20 and 40°C. Preferably the reaction will proceed at room temperature.
• the pH of the reaction mixture will vary between 5 and l0, more usually between 6 and 9.
• the concentration of various reagents will depend on the level of analyte expected in the test medium, with such level usually being between l0 ⁇ 3 and l0 ⁇ 12M.
• the method according to the invention has an extremely wide field of application. In principle it can be applied to the detection and/or quantitative determination of any substances for which specific binding proteins exist.
• substances comprise but are not limited to cell surface and tissue antigens, biological substances excreted by or derived from living organisms, particularly biological substances occurring in biological fluids such as saliva, lymph, blood and its derived fractions such as, plasma and serum, urine, cerebrospinal fluid, amnion fluid, etc.
• Substances which can be detected include, proteins, polypeptides, peptides, like enzymes, hormones, structural proteins; nucleic acids; vitamins; polysaccharides; toxins; alkaloids; glycoproteins; haptens; metabolites; pharmacological agents; steroids, and any other molecules for which a specific binding counterpart exists in biological systems or can be synthesized.
• Representative protein analytes include the classes of protamines, mucoproteins, glycoproteins, globulins, albumins, scleroproteins, phosphoproteins, histones, lipoproteins, chromoproteins, and nucleoproteins.
• proteins examples include prealbumin, ⁇ 1-lipoprotein, human serum albumin, ⁇ 1-acid glycoprotein, ⁇ 1-antitrypsin, ⁇ 1-glycoprotein, transcortin, thyroxine binding globulin, haptoglobin, hemoglobin, myoglobin, ceruloplasmin, ⁇ 2-­lipoprotein, ⁇ 2-macroglobulin, ⁇ -lipoprotein, erythroprotein, transferin, hemopexin, fibrinogen, the immunoglobulins such as IgG, IgM, IgA, IgD, and IgE, and their fragments, e.g., F c and F ab , complement factors, prolactin, blood clotting factors such as fibrinogen, thrombin and so forth, insulin, melanotropin, somatotropin, thyrotropin, follicle stimulating hormone, luteinizing hormone, gonadotropin, thryroid stimulating hormone, placental lactogen
• hapten analytes include the general classes of drugs, metabolites, hormones, vitamins, and the like organic compounds.
• Haptenic hormones include thyroxine and triidothyronine.
• Vitamins include vitamins A, B, e.g., B12, C, D, E and K, folic acid and thiamine, Drugs include antibiotics such as aminoglycosides, e.g., gentamicin, tobramycin, amidacin, sisomicin, kanamycin, and netilmicin, penicillin, tetracycline, terramycin, chloromycetin, and actinomycetin; nucleosides and nucleotides such as adenosine diphosphate (ADP) adenosine triphosphate (ATP), flavin mononucleotide (FMN), nicotinamide adenine dinucleotide (NAD) and its phosphate derivative (NADP), thymidine,
• cardiac glycosides and derivatives of benzodiazepine, benzimidazole, piperidine, piperazine, imidazole, triazole, pyridazine, l,2,4-triazinedione or 2,3,5,6-­tetrahydro-imidazo[2,l-b]thiazoles, or amides, hydratropic acid derivatives or trialkylamines.
• Benzimidazole derivatives comprise thiabendazole, fuberidazole, ciclobendazole, oxibendazole, parbendazole, cambendazole, mebendazole, fenbendazole, flubendazole, albendazole, oxfendazole, nocodazole and astemizole.
• Piperidine derivatives comprise diphenoxylate, phenoperidine, haloperidol, haloperidol decanoate, bromperidol decanoate, bromperidol, moperone, trifluperidol, pipamperone, piritramide, fentanyl, benperidol, droperidol, benzitramide, benzetimide, domperidone, sufentanil, carfentanil, alfentanil, dexetimide, milenperone, difenoxin, fluspirilene, penfluridol, pimozide, lorcainide, loperamide, astemizole, ketanserine, levocabastine, cisapride, altanserin, ritanserin, 3-[2-[4-(4-­fluorobenzoyl)-l-piperidinyl]ethyl]-2,7-dimethyl-4 H -pyr
• Piperazine derivatives include azaperone, fluanisone, lidoflazine, flunarizine, mianserine, oxatomide, mioflazine, clocinizine and cinnarizine.
• imidazole derivatives are metronidazole, ornidazole, ipronidazole, tinidazole, isoconazole, nimorazole, miconazole, burimamide, metiamide, metomidate, enilconazole, or imazalil, etomidate, econazole, clotrimazole, carnidazole, cimetidine, doconazole, sulconazole, parconazole, orconazole, butoconazole, triadiminole, tioconazole, valconazole, fluotrimazole, ketoconazole, oxiconazole, lombazole, bifonazole, oxmetidine, fenticonazole, tubulazole and (Z)-l-[2-chloro-2-(2,4-dichlorophenyl)ethenyl]-l H -imidazole.
• Triazole derivatives comprise virazole, azaconazole, etaconazole, propiconazole, penconazole, itraconazole and terconazole.
• Pyridazine derivative comprise for example, 3-chloro-6-[3,6-­dihydro-4-(3-methylphenyl)-l(2 H )-pyridinyl]pyridazine, 3-methoxy-6-[4-­(3-methylphenyl)-l-piperazinyl]pyridazine and the compounds of Publ. Eur. Pat. Appl. No. 0,l56,433.
• l,2,4-Triazinediones comprise for example, 2-chloro- ⁇ -(4-chloro­phenyl)-4-(4,5-dihydro-3,5-dioxo-l,2,4-triazin-2(3 H )-yl)benzeneaceto­nitrile, 2,6-dichloro- ⁇ -(4-chlorophenyl)-4-(4,5-dihydro-3,5-dioxo-­l,2,4-triazin-2(3 H )-yl)benzeneacetonitrile and the compounds of Publ. Eur. Pat. Appl. No. 0,l70,3l6.
• Trialkylamines are, for example, diisopromine, prozapine.
• 2,3,5,6-Tetrahydro-imidazo[2,l-b]thiazoles comprise, for example, tetramisole or levamisole.
• Amides comprise for example, closantel, ambucetamide, isopropamide, buzepide metiodide, dextromoramide.
• a hydratropic acid derivative is, for example, suprofen.
• the purposes of the determinations can be multiple. In certain applications they will be used merely as a scientific tool, to visualize particular substances, e.g. on histological coupes, on chromatograms, electrophoretograms, blots, etc. For example, when applying different lables to different specific proteins or other bindable substances on a chromatogram, electrophoretogram, protein blot etc., a reference pattern is obtained which can advantageously be used to localize other proteins or other substances.
• the method of the invention will find utility in a wide variety of diagnostic tests such as, for example, the following: the detection and characterisation of subpopulations of T-lymphocytes; pregnancy tests based on the presence of certain hormones (choriotrophic gonadotropin) in the urine, diagnostic tests for various infections diseases of i.a. fungal, bacterial and in particular viral origin, such as, for example, hepatitis B, auto-immune-diseases (AIDS), gonorrhoea, rubella, poliomyelitis, etc.
• diagnostic tests such as, for example, the following: the detection and characterisation of subpopulations of T-lymphocytes; pregnancy tests based on the presence of certain hormones (choriotrophic gonadotropin) in the urine, diagnostic tests for various infections diseases of i.a. fungal, bacterial and in particular viral origin, such as, for example, hepatitis B, auto-immune-diseases (AIDS), gonorrhoea,
• Diagnostics for metabolic, endocrinological and various endogenous diseases including diagnostics for the detection of congenital malfunctions of embryo's based on the presence of specific proteins in the amnion fluid.
• multivalent diagnostics can be prepared which allow the simultaneous detection and/or determination of more than one bindable substance.
• the method lends itself particularly for routine tests, not only for use by specialists and technicians in the laboratory, but also for use by laymen who have no skills in the relevent technical field.
• the method can also be easily automated which is an important factor when large numbers of identical determinations must be carried out, e.g. in blood banks and specialized clinical laboratories.
• the invention further comprises reagent systems which comprise all of the essential chemical elements required to conduct a desired assay method encompassed by the present invention.
• the reagent system is presented in a commercially packaged form, as a composition or admixture where the compatability of the reagents will allow, in a test device configuration, or as a test kit, i.e., a packaged combination of one or more containers holding the necessary reagents. Included in the reagent system are the reagents appropriate for the binding reaction system desired, always requiring a labelled reagent and the other components necessary to produce the signal-generating reaction.
• binding reaction reagents can include, in addition to the labelled reagent, a binding counterpart to the analyte, and so forth.
• the reagent system can include other reagents as are known in the art and which may be desirable from a commercial and user standpoint, such as buffers, diluents, standards, and so forth.
• the invention comprises test kits for the qualitative or quantitative determination of specific bindable substances which comprise, besides other reagents, an aqueous suspension of latex particles which are coated with specific binding proteins to said bindable substances or to primary specific binding proteins to said bindable substances.
• the suspensions of the colour coupler latexes M1, C2 and Y1 used in these examples have the following compositions:
• a suspension of colour coupler latex M1, C2 and Y1 was diluted to a 2% (polymer content) suspension using a sodium carbonate dilution buffer (0.0l5 M Na2CO3, 0.035 M NaHCO3, 0.2 g/l NaN3, pH 9.3).
• a protein (antibody) solution, containing 0.5 mg/ml affinity-purified goat anti-mouse immunoglobulin was added to 5 ml of the latex suspension.
• Latex-antibody complexes were reacted with antigen which was fixed to a nitrocellulose membrane.
• a dilution series of the antigen was made in a buffer consisting of 0.02 M Tris(hydroxymethyl)aminoethane - 0.l5 M NaCl - 0.5 g/l NaN3, (pH 8.2, with HCl) with 50 ⁇ g/ml albumin as carrier.
• a concentration series of 250 - l25 - 62.5 - 3l - l5.5 - 7.75 - 3.9 - l.9 - 0.8 and 0.4 ng/ ⁇ l was prepared and l ⁇ l thereof was spotted onto nitrocellulose strips (0.6 ⁇ 6cm).
• nitrocellulose strips were treated with 0.05 M sodium phosphate (pH 7.5) - 5% (v/v) Tween® solution for 30 minutes at 37°C, and subsequently washed three times with water for l0 min.
• 0.05 M sodium phosphate (pH 7.5) - 5% (v/v) Tween® solution for 30 minutes at 37°C, and subsequently washed three times with water for l0 min.
• albumin instead of immunoglobulin (antigen) were in the same way spotted.
• the nitrocellulose strips were incubated for 2-3 hours with the latex suspension, prepared as mentioned above.
• the optimal concentration of protein (antibodies) to be coupled to the latex was determined in the following test procedure. A series of solutions of various concentration, (antibody concentrations of 2 - l - 0.5 - 0.l mg/ml) was added to 5 ml of the 2% latex suspension. The thus obtained mixtures were further treated following the same described hereinabove. The colour intensities obtained with the latex-antibody complexes prepared with the various concentrations of antibody were compared. It appeared that the optimal concentration of antibodies was 0.5 mg/ml since higher concentrations gave no increase of colour intensity of the spots, lower concentrations gave less intensity.
• the detection sensitivity is defined as the minimal detectable spot in the antigen dilution series. This sensitivity varies with the type of latex. In a typical experiment the following sensitivities were found: colour coupler latex M1 l.9 ng/ ⁇ l; colour coupler latex Y1 l5.5 ng/ ⁇ l; colour coupler latex C2 7.7 ng/ ⁇ l.
• a suspension of colour coupler latex C1 was diluted to 2% (polymer content) in a sodium carbonate dilution buffer (0.0l5 M Na2CO3, 0.035 M NaHCO3, 0.2 g/l NaN3, pH 9.3).
• l25 mg normal human immunoglobulin dissolved in 5ml of the aforementioned carbonate buffer were mixed with 250 ml of the diluted latex suspension. This mixture was stirred overnight at room temperature to allow the immunoglobulin to adsorb on the latex beads.
• l00 ml of a 5% (w.v) bovine serum albumin (BSA) solution in a 50 mM phosphate buffer at pH 7.5 were added to the stirred mixture which was then put at 37°C for 30 min.
• the remaining unbound immunoglobulin and BSA were washed away from the latex particles with phosphate-BSA-Tween®-NaCl buffer (0.05 M sodium phosphate, 5 g/l BSA, 5 ml/l Tween 20®, l M NaCl, 0.5 g/l NaN3, pH 7.5).
• the latex suspension was then brought at the original volume of 250 ml in the same phosphate-BSA-Tween®-NaCl buffer.
• a suspension of colour coupler latex M1 was diluted to 2% (polymer content) in the carbonate buffer described hereinabove. 2 ml of anti-C-reactive protein (anti-CRP) antibodies (39.6 mg/ml), were mixed with 250 ml of the diluted latex suspension. This mixture was stirred overnight at room temperature.
• anti-CRP anti-C-reactive protein
• the latex particles were washed in glycin-Triton-SDS® buffer (0.l M glycin, 0.l M NaCl, 0.l2 mg/ml NaOH, l g/l NaN3, l ml/l Triton X705® 50%, l4 mg/l sodium dodecyl sulphate (SDS). Afterwards, the suspension was diluted ten times in a 50 mM phosphate buffer (pH 7.5) containing 5% (w/v) BSA, and kept at 37°C for 30 min. The latex particles were then washed in the phosphate-BSA-Tween®-NaCl buffer described hereinabove. During this process, the volume of the latex suspension was reduced to the original 250 ml.
• glycin-Triton-SDS® buffer 0.l M glycin, 0.l M NaCl, 0.l2 mg/ml NaOH, l g/l NaN3,
• Sticks (5 ⁇ l00 mm) were made out of 0.2 mm polyester sheets. One 5 ⁇ 5 mm human immunoglobulin-containing piece of filter paper and one 5 ⁇ 5 mm anti-CRP antibody-containing piece of filter paper were glued next to each other, close to one edge of the stick. Care was taken to leave a l mm gap between both pieces of paper. The glue was allowed to dry at room temperature overnight. The assembled dip-sticks were stored at 4°C.
• 0.5 to l ml of a patient's serum was put in a l0 ml polystyrene test tube.
• the dip-stick was added for 30 to 60 min in a way that both activated sites were properly immersed.
• the dip-stick was then washed with running tap water for about l0 s.
• the stick was put in a mixture of l ml anti-CRP colour coupled latex and l ml anti-rheumatoid factor colour coupled latex for 30 to 60 min.
• the dipstick was washed again with tap water and held for a few seconds in a l0% persulfate solution.
• the colour was developed by immersing the stick for about five seconds in a developer containing 4-(butyl, N - ⁇ -sulfobutyl)amino-aniline as developing agent.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Immunology (AREA)
• Engineering & Computer Science (AREA)
• Molecular Biology (AREA)
• Biomedical Technology (AREA)
• Chemical & Material Sciences (AREA)
• Hematology (AREA)
• Urology & Nephrology (AREA)
• Food Science & Technology (AREA)
• General Physics & Mathematics (AREA)
• Cell Biology (AREA)
• Biotechnology (AREA)
• Medicinal Chemistry (AREA)
• Physics & Mathematics (AREA)
• Analytical Chemistry (AREA)
• Biochemistry (AREA)
• General Health & Medical Sciences (AREA)
• Microbiology (AREA)
• Pathology (AREA)
• Investigating Or Analysing Biological Materials (AREA)
• Paper (AREA)
• Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
• Peptides Or Proteins (AREA)
• Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
• Plural Heterocyclic Compounds (AREA)
• Adhesives Or Adhesive Processes (AREA)

Priority Applications (1)

Applications Claiming Priority (2)

Publications (3)

Family

ID=25210046

Family Applications (1)

Country Status (7)

Cited By (12)

Families Citing this family (232)

Citations (10)

Family Cites Families (6)

• 1986
  • 1986-12-04 CA CA000524512A patent/CA1291031C/fr not_active Expired - Lifetime
  • 1986-12-10 DE DE8686202231T patent/DE3688184T2/de not_active Expired - Lifetime
  • 1986-12-10 EP EP86202231A patent/EP0227173B1/fr not_active Expired - Lifetime
  • 1986-12-10 AT AT86202231T patent/ATE87743T1/de not_active IP Right Cessation
  • 1986-12-10 ES ES86202231T patent/ES2054617T3/es not_active Expired - Lifetime
  • 1986-12-15 US US06/941,446 patent/US4837168A/en not_active Expired - Lifetime
  • 1986-12-23 JP JP61305543A patent/JP2509201B2/ja not_active Expired - Lifetime
• 1994
  • 1994-05-16 US US08/243,425 patent/US5498551A/en not_active Expired - Lifetime

Patent Citations (10)

Also Published As

Similar Documents

Legal Events